Injection Flu Shot Market Research Report
On Oct 29, Global Info Research released "Global Injection Flu Shot Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031". This report includes an overview of the development of the Injection Flu Shot industry chain, the market status of Injection Flu Shot Market, and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Injection Flu Shot.
According to our (Global Info Research) latest study, the global Injection Flu Shot market size was valued at US$ 9399 million in 2024 and is forecast to a readjusted size of USD 13786 million by 2031 with a CAGR of 5.4% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
An Injection Flu Shot is a type of biological product administered via intramuscular injection to prevent seasonal or epidemic influenza infections caused by influenza viruses. The product typically contains viral antigens produced through inactivation or recombinant technologies, which stimulate the immune system to generate protective antibodies against specific flu strains, thereby reducing infection risk and disease severity. Depending on the manufacturing technology, injection flu shots can be classified into inactivated vaccines, recombinant protein vaccines, and mRNA-based vaccines. They are widely used in public immunization programs, elderly and chronic patient protection, and emergency pandemic preparedness. As one of the most established and globally adopted vaccine categories, the flu shot plays a vital role in the global infectious disease prevention network.In 2024, global XXXX production reached approximately 842 million units, with an average global market price of around US$ 10.8 perunit.
With the enhancement of global infectious disease prevention systems and growing public health awareness, the injection flu shot market is entering a new growth phase. Governments worldwide are promoting annual influenza vaccination programs and prioritizing immunization coverage as a national health objective, providing strong policy support. The adoption of recombinant protein and mRNA vaccine technologies has accelerated production cycles and improved strain matching. Moreover, the aging population and rising prevalence of chronic diseases are driving higher demand among high-risk groups, while expanding vaccination networks in hospitals and retail pharmacies further boost market momentum.Despite strong prospects, the flu shot market faces multiple challenges. Rapid viral mutation increases vaccine update frequency and R&D costs, causing fluctuations in annual effectiveness and public confidence. Manufacturing requires high-standard sterile environments and cold-chain logistics, making production vulnerable to raw material disruptions. In some regions, price controls, lengthy approval timelines, and inconsistent public procurement policies pressure profitability. Intensifying global competition means new entrants must possess robust R&D and distribution capabilities to gain market traction.Demand for injection flu shots is shifting from centralized government procurement to diversified markets, with private clinics, retail pharmacies, and online booking platforms emerging as growth engines. Rising consumer health awareness is transforming influenza vaccination from policy-driven to demand-driven. The introduction of multivalent vaccines, personalized vaccination services, and combination immunization products is pushing the market toward higher value-added segments. Governments are also strengthening influenza surveillance and data-sharing systems to improve vaccine matching and rollout efficiency.Core raw materials for flu shot production include viral antigens, culture media, adjuvants, and formulation excipients. Traditional egg-based manufacturing is being complemented by cell-based and recombinant protein technologies, enhancing consistency and scalability. With the rapid expansion of mRNA vaccine platforms, demand for key materials such as modified nucleotides and lipid nanoparticles (LNPs) has surged, driving upstream specialization and localization. Meanwhile, tighter global supply conditions and stricter quality standards are pushing manufacturers to strengthen traceability and establish long-term supplier partnerships to ensure product safety and production continuity. The average gross profit margin of this product is 57% and the global capacity is about 900 million units.
This report is a detailed and comprehensive analysis for global Injection Flu Shot market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Sample Report Request Injection Flu Shot
https://www.globalinforesearch.com/reports/3050744/injection-flu-shot
Market segment by Type: Trivalent Influenza Vaccine、 Quadrivalent Influenza Vaccine
Market segment by Application: 6 Months to 3 Years、 > 3 Years
Major players covered: Sanofi、 CSL、 GSK、 Viatris、 AstraZeneca、 Hualan Bio、 Changchun Institute of Biological、 Sinovac、 Jiangsu GDK、 KM Biologics、 BCHT
Market segment by region, regional analysis covers: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia),South America (Brazil, Argentina, Colombia, and Rest of South America),Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa).
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Injection Flu Shot product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Injection Flu Shot, with price, sales, revenue and global market share of Injection Flu Shot from 2020 to 2025.
Chapter 3, the Injection Flu Shot competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Injection Flu Shot breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Injection Flu Shot market forecast, by regions, type and application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Injection Flu Shot.
Chapter 14 and 15, to describe Injection Flu Shot sales channel, distributors, customers, research findings and conclusion.
Data Sources:
Via authorized organizations:customs statistics, industrial associations, relevant international societies, and academic publications etc.
Via trusted Internet sources.Such as industry news, publications on this industry, annual reports of public companies, Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), Trading Economics, News Network, Statista, Federal Reserve Economic Data, BIS Statistics, ICIS, Companies House Documentsm, investor presentations, SEC filings of companies, etc.
Via interviews. Our interviewees includes manufacturers, related companies, industry experts, distributors, business (sales) staff, directors, CEO, marketing executives, executives from related industries/organizations, customers and raw material suppliers to obtain the latest information on the primary market;
Via data exchange. We have been consulting in this industry for 16 years and have collaborations with the players in this field. Thus, we get access to (part of) their unpublished data, by exchanging with them the data we have.
Via our long-term tracking and gathering of data from this industry.We have a database that contains history data regarding the market.
About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
